Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate

With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review